Title: Compositions and Methods for Treating Trail-Resistant Cancer Cells. Number: 20040126791. Filed: Sept. 19, 2003. Lead Inventor: Harald Wajant, Ribopharma (Alnylam).
The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of a cellular FLICE-like inhibitory protein gene, comprising a complementary RNA strand [that] is substantially identical to at least a part of a cFLIP gene.”